Summary
Edwards Lifesciences Corp (EW) filed an 8-K on October 23, 2018, primarily to report its financial results for the third quarter of 2018. The filing includes a press release detailing the company's performance during the period. Investors should review this press release for key financial metrics, operational updates, and any forward-looking statements or guidance provided by the company. This report is crucial for understanding the company's recent financial health and its trajectory moving forward.
Key Highlights
- 1Disclosure of Q3 2018 financial results via press release.
- 2Press release is incorporated by reference into the 8-K filing.
- 3The information furnished is not deemed "filed" for purposes of the Securities Exchange Act of 1934.
- 4This 8-K serves as an official notification of the company's quarterly financial performance.
- 5Key financial and operational details are expected to be within the furnished press release (Exhibit 99.1).
Frequently Asked Questions
The main purpose of this 8-K filing is to officially report Edwards Lifesciences' financial results for the third quarter of 2018, as detailed in an accompanying press release.
The specific financial results for Q3 2018 are contained within the press release dated October 23, 2018, which is furnished as Exhibit 99.1 to this 8-K filing.
This 8-K filing itself does not contain updated guidance, but the accompanying press release (Exhibit 99.1) is likely to include any forward-looking statements or updated guidance provided by Edwards Lifesciences for the remainder of 2018.
No, the information furnished under Item 2.02 of this 8-K, including the press release, is explicitly stated as not being considered 'filed' for the purposes of the Securities Exchange Act of 1934.